All B-ALL patients n=18 | |
Age at CART1, median (range), years | 18.5 (7–30) |
Age at CART2, median (range), years | 19 (8–31) |
Sex, n (%) | |
Male | 16 (88.9) |
Female | 2 (11.1) |
Race, n (%) | |
White | 12 (66.7) |
Asian | 2 (11.1) |
Multiple and unknown | 4 (22.2) |
Ethnicity, n (%) | |
Hispanic | 3 (16.7) |
Non-Hispanic | 15 (83.3) |
Prior no of lines of therapy excluding CART1, median (range) | 6 (2–13) |
Prior HSCT, n (%) n=14 | |
1 | 11 (61.1) |
>1 | 3 (16.7) |
Prior Immunotherapy, n (%) n=8 | |
Prior blinatumomab | 6 (33.3) |
Prior inotuzumab ozogamicin | 2 (11.1) |
Prior alternate CAR T-cell therapy, n (%) n=9 (prior to CART1) | |
Prior anti-CD19 CAR | 6 (33.3) |
Prior anti-CD22 CAR | 2 (11.1) |
Prior anti-CD19/22 CAR | 1 (5.6) |
B-ALL, B-cell acute lymphoblastic leukemia; CAR, chimeric antigen receptor; HSCT, hematopoietic stem cell transplantation.